Skip to main content

Table 1 Frequencies of CTLA-4 polymorphisms in melanoma patients and healthy controls

From: Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

 

Controls

Melanomas

 
 

Number (N = 288)

%

Number (N = 286)

%

P

AG 49

A/A

152

52.8

132

46.2

0.27

A/G

111

38.5

128

44.8

 

G/G

25

8.7

26

9.1

 

CT 318

C/C

230

79.9

229

80.1

0.94

C/T

57

19.8

55

19.2

 

T/T

1

0.4

2

0.7

 

CT 60

A/A

90

31.3

65

22.7

0.071

A/G

135

46.9

151

52.8

 

G/G

63

21.9

70

24.5

 

JO 27

C/C

90

31.3

73

25.5

0.32

C/T

143

49.7

153

53.5

 

T/T

55

19.1

60

21.0

 

JO 30

A/A

95

33.0

72

25.2

0.12

A/G

138

47.9

151

52.8

 

G/G

55

19.1

63

22.0

 

JO 31

T/T

96

33.3

71

24.8

0.047

G/T

144

50.0

151

52.8

 

G/G

48

16.8

64

22.4

Â